Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

This Small-Cap Stock Could 10x by 2030, But It’s Not for the Faint of Heart

Ardelyx (ARDX) is emerging as a compelling, yet risky, small-cap biotech opportunity. The company has made significant progress with two first-in-class therapies: IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.

Valued at $1.07 billion, Ardelyx stock has returned 542% over the last three years. With revenue growing and commercial execution improving, Ardelyx is positioning itself for potentially explosive growth.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.